A Phase I Clinical Study of Dual Specificity CD19 and CD22 Chimeric Antigen Receptor T Cell Therapy in Relapsed or Refractory Lymphoma
Phase of Trial: Phase I
Latest Information Update: 21 Feb 2019
At a glance
- Drugs LCAR L10D (Primary)
- Indications B-cell lymphoma
- Focus Adverse reactions
- 10 Feb 2019 Planned number of patients changed from 12 to 9.
- 10 Feb 2019 Planned initiation date changed from 18 Sep 2018 to 18 Feb 2018.
- 27 Jul 2018 New trial record